Novartis Fined $422.5M in Marketing, Kickback Case

Novartis fined $422.5M in marketing, kickback case
Novartis Pharmaceuticals Corp. will pay $422.5 million in penalties for marketing an epilepsy medicine for unapproved uses and for paying kickbacks to doctors to prescribe it and five other drugs, federal officials announced.

Read more on The Indianapolis Star

Tags: marketing, indianapolis star, epilepsy medicine, Law Crime, kickback case

Related Epilepsy Posts

• Novartis agrees to $422.5m in fines
• US epilepsy drug delay
• November is Epilepsy Awareness Month
• Epilepsy Causes Symptoms Information With Treatment
• Epilepsy Causes, Symptoms and Treatments